The sole holder of Mangoceuticals' Series B Preferred Stock approved the creation of a new 8% Series D Convertible Cumulative Preferred Stock series and an amendment to the Series B designation. This approval permits the company to sell up to 1,000,000 shares of Series D stock at $10.00 per share in a Regulation A offering, potentially raising $10 million. The filing also announces that the combined 2025 and 2026 Annual Meeting will be held on December 30, 2026. Mangoceuticals develops and markets health and wellness products.
